Implementation of IVS3 for Upper Limb Motor Recovery
Launched by WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY · Jun 28, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the use of a device called IVS3 to help improve arm and hand movement in people who have had a stroke. The researchers want to see how satisfied participants are with the treatment and how well it helps them regain function in their upper limbs. They believe that using the IVS3 device will be a safe and effective way for patients to receive therapy in an outpatient setting, which means they can go home after their sessions instead of staying in a hospital.
To join the study, participants need to be at least 18 years old, speak English, and have had a stroke at least six months prior. They should have some difficulty using their arm or hand, but not too severe. People who have certain conditions, like severe muscle stiffness or significant vision problems, won't be eligible. If you join, you can expect to use the IVS3 device as part of your therapy and share your thoughts about how it's working for you. This study is currently looking for participants, and anyone interested should consider whether they meet the criteria and if they want to take part.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥ 18 years old
- • 2. English speaking
- • 3. History of ischemic or hemorrhagic stroke ≥ 6 months prior to study enrolment
- • 4. FMA-UE: 20 \< x \< 50 (moderate impairments)
- • 5. With or without hemi spatial neglect
- Exclusion Criteria:
- • 1. Spasticity or increased tone with MAS ≥3 in the upper extremity
- • 2. Unable to communicate effectively or provide informed consent
- • 3. Significant visual impairments
- • 4. Concurrent occupational therapy being received outside of the study
- • 5. Pregnant or incarcerated individuals
About Weill Medical College Of Cornell University
Weill Medical College of Cornell University is a leading academic institution dedicated to advancing medical research and education. As a prominent sponsor of clinical trials, it focuses on innovative healthcare solutions and the development of new therapies across various medical disciplines. The institution is committed to fostering collaborative research efforts that enhance patient care and improve health outcomes. With a robust infrastructure and a team of experienced researchers and clinicians, Weill Cornell aims to translate scientific discoveries into practical applications, ensuring a strong emphasis on ethical standards and regulatory compliance throughout the clinical trial process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Joan Stilling, MD,MS
Principal Investigator
Weill Medical College of Cornell University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported